(Q27851711)

13 November 2016

title

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. (English)

1 reference

PubMed publication ID

13 November 2016

1 reference

Federica Di Nicolantonio

0 references

0 references

Chong Sun

0 references

René Bernards

0 references

Davide Zecchin

0 references

author name string

Anirudh Prahallad

0 references

Sidong Huang

0 references

Ramon Salazar

0 references

Roderick L Beijersbergen

BRAF mutations in hairy-cell leukemia

0 references

language of work or name

English

0 references

publication date

26 January 2012

0 references

1 reference

483

0 references

issue

7387

0 references

page(s)

100-3

0 references

cites work

1 reference

12 December 2020

Mutations of the BRAF gene in human cancer

1 reference

12 December 2020

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

1 reference

12 December 2020

The protein kinase complement of the human genome

1 reference

12 December 2020

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

12 December 2020

EGFR in melanoma: clinical significance and potential therapeutic target

1 reference

12 December 2020

Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis

1 reference

12 December 2020

Identification of epidermal growth factor receptor as a target of Cdc25A protein phosphatase

1 reference

12 December 2020

KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial

1 reference

12 December 2020

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

1 reference

12 December 2020

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

12 December 2020

The concept of synthetic lethality in the context of anticancer therapy

1 reference

12 December 2020

Regulation of Cdc25C by ERK-MAP kinases during the G2/M transition

1 reference

12 December 2020

High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma

1 reference

12 December 2020

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

1 reference

12 December 2020

ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome

1 reference

12 December 2020

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

1 reference

12 December 2020

An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors

1 reference

12 December 2020

BRAF mutations are associated with some histological types of papillary thyroid carcinoma

1 reference

12 December 2020

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

12 December 2020

BRAFMutation in Metastatic Colorectal Cancer

1 reference

12 December 2020

Moyamoya disease and moyamoya syndrome

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FNATURE10868

7 January 2021